Summary
HPTLC densitometry and HPLC are considered for the determination of azidothymidine and its degradation product thymine in pharmaceutical dosage forms. In HPTLC the substances were separated on silica gel with fluorescence indicator in methanol-chloroform (10∶90) and methanol-chloroform (15∶85) systems. Absorbance measurement (detection of reflectance) of the separated substances was carried outin situ at 268 nm using four-level calibration (external standard, linear regression function) in the concentration range of 25–100 ng thymine/spot and using single-level calibration (external standard) at the concentration of 100 ng azidothymidine/spot. HPLC was carried out using RP-18 stationary phase and methanol+aqueous 0.03 mol/l KH2PO4 (18+82, v/v) as the mobile phase. The temperature was 50°C and the detection wavelength 266 nm. The detection limit of thymidine was 0.05%. The concentration range for azidothymidine was 0.5–1.5 mg/ml and for thymine 1–40 μg/ml (for an injection volume of 10 μl). The results were evaluated by linear regression analysis.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
J. P. Horowitz, J. Chua, M. Noet, J. Org. Chem.,29, 2076 (1964).
H. Mitsuya, K. J. Weinhold, P. A. Furman, M. H. Stclair, S. N. Lehrman, R. C. Gallo, D. Bolognesi, D. W. Barry, S. Broder, Proc. Natl. Acad. Sci. USA82, 7096 (1985).
W. P. Parks, E. S. Parks, J. Acquired Immune Deficiency Syndromes,1, 125 (1988).
E. D. Bashaw, M. A. Amantea, Amer. J. Hospital Pharmacy,45, 2532 (1988).
M. A. Skinner, T. J. Matthews, J. Acquired Immune Deficiency Syndrome1, 162 (1988).
V. Herbert, S. Hirschman, JAMA,260, 3586 (1988).
I. V. D. Weller, A. Mills, British Medical J.,297, 1608 (1988).
S. E. Keller, S. J. Schleifer, J. A. Bartlett, R. L. Johnson, JA MA,260, 3586 (1988).
H. D. Langtry, D. M. Campoli-Richards, Drugs,37, 40 (1989).
P. A. Cload, J. Infection18, Suppl. 1, 15 (1989).
I. Williams, G. Gabriel, H. Cohen, P. Williams, R. S. Tedde, S. Machin, I. V. D. Weller, J. Infection, Suppl.1, 23 (1989).
J. M. Yeo, J. Infection18, Suppl. 1, 93 (1989).
L. E. Mathes, G. Muschik, L. Demby, P. Polas, D. W. Melini, H. J. Issaq, R. Sams, J. Chromatogr.,432, 346 (1988).
J. D. Unadkat, S. S. Crosby, J. P. Wang, C. C. Hertel, J. Chromatogr.,430, 420 (1988).
M. A. Hedaya, R. J. Sawchuk, Clin. Chem.,34, 1565 (1988).
S. S. Good, D. J. Reynolds, P. de Miranda, J. Chromatogr.431, 123 (1988).
M. R. Blum, S. H. T. Liao, S. S. Good, P. de Miranda, Amer. J. Med.,85, Suppl. 2A, 189 (1988).
W. J. M. Underberg, U. K. Underberg-Chitoe, O. Bekers, L. Meenhorst, J. H. Beijnen, Internat. J. Pharmaceutics,50, 175 (1989).
Analytical Procedures — Azidothymidin tablets, Lachema Czechoslovakia, 1989.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Tománková, H., Šabartová, J. Determination of azidothymidine and its degradation product thymine in pharmaceutical dosage forms by HPLC and HPTLC densitometry. Chromatographia 29, 44–50 (1990). https://doi.org/10.1007/BF02261138
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF02261138